About BiomeSense
BiomeSense is a company based in Chicago (United States) founded in 2018 by Jack Gilbert, Savas Tay, and Kevin Honaker. BiomeSense has raised $8.43 million across 5 funding rounds from investors including HHS, Bluestein Ventures and Harvest Ridge Capital. The company has 9 employees as of December 31, 2024. BiomeSense offers products and services including GutLab Technology, MetaBiome AI Platform, and Full Laboratory Services. BiomeSense operates in a competitive market with competitors including Seed, Omega Therapeutics, Azitra, OptiBiotix Health and OGI Bio, among others.
- Headquarter Chicago, United States
- Employees 9 as on 31 Dec, 2024
- Founders Jack Gilbert, Savas Tay, Kevin Honaker
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8.43 M (USD)
in 5 rounds
-
Latest Funding Round
$6.18 M (USD), Seed
Feb 14, 2023
-
Investors
HHS
& 6 more
-
Employee Count
9
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of BiomeSense
BiomeSense offers a comprehensive portfolio of products and services, including GutLab Technology, MetaBiome AI Platform, and Full Laboratory Services.
Enables continuous at-home gut microbiome monitoring for research.
Analyzes microbiome data to identify patterns and clinical insights.
Offers sequencing and support for microbiome data generation.
Funding Insights of BiomeSense
BiomeSense has successfully raised a total of $8.43M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $6.18 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BiomeSense
BiomeSense has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Bluestein Ventures and Harvest Ridge Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are provided in the food industry.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Venture capital and accelerator services are provided across multiple sectors.
|
Locked | Locked | Locked |
Investor details for BiomeSense
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BiomeSense
Investment portfolio details for BiomeSense
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BiomeSense
Detailed financials for BiomeSense
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biomesense Comparisons
Peer comparison for BiomeSense
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BiomeSense
BiomeSense operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Seed, Omega Therapeutics, Azitra, OptiBiotix Health and OGI Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Synbiotics are developed for simulating the gut microbiome.
|
|
| Locked | Locked | Locked |
Platform for human genome study is provided for precision medicine.
|
|
| Locked | Locked | Locked |
Microbiome-based therapeutics for skin conditions like eczema are developed.
|
|
| Locked | Locked | Locked |
Microbial strains are developed for treating human metabolic diseases.
|
|
| Locked | Locked | Locked |
Modular automation system for routine microbial culturing is provided.
|
Detailed competitors of BiomeSense
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biomesense
Complete news archive for BiomeSense
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BiomeSense
BiomeSense was founded in 2018 and raised its 1st funding round 1 year after it was founded.
BiomeSense is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Kevin Honaker is the current CEO of BiomeSense. They have also founded this company.
BiomeSense is a funded company, having raised a total of $8.43M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at BiomeSense is 9.
Developer of AI-enabled technology platform for microbiome data generation and analysis. The company provides continuous, comprehensive microbiome data and AI-enabled bioinformatics. It offers GutLab technology for continuous tracking of the patients gut microbiome throughout the treatment journey. The companys MetaBiome AI Platform transforms and analyzes the data using time-series analyses, enabling identification of clinically-relevant shifts and patterns. The platform unlocks host-microbiome interactions, such as a signature suggesting the gut microbiome may be a biomarker for active tumor burden. The company partners with scientists, institutions, and companies conducting clinical research into the gut microbiome, with a focus on personalized biomarker discovery and product development.
BiomeSense's top competitors include Omega Therapeutics, Azitra and Seed.
BiomeSense offers GutLab Technology, MetaBiome AI Platform, and Full Laboratory Services.
BiomeSense has 7 investors. Key investors include HHS, Bluestein Ventures, Harvest Ridge Capital, Seerave Foundation, and SOSV.